Category: ALK Positive News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
ALK Positive Grants Support Dr. Alice Shaw’s Pioneering ALK-Positive Lung Cancer Research
ALK Positive is proud to support Dr. Alice Shaw’s pre-clinical research advancing the understanding of ALK-positive lung cancer. Her work focuses on uncovering biological mechanisms that drive treatment resistance, with the goal of informing future therapeutic strategies and improving long-term outcomes for patients. Through this partnership, ALK Positive is investing in science that accelerates progress…
-
ALK Positive and Pfizer Announce New Grant Opportunity to Improve Education and Support for People Living With Advanced ALK+ Lung Cancer
We’re proud to partner with Pfizer on a new grant opportunity designed to strengthen education for people diagnosed with advanced ALK-positive lung cancer. This RFP supports independent projects that help patients and care partners prepare for treatment, recognize side effects early, and access clear, inclusive resources that honor their preferences. Funding is available for organizations…
-
ALK Positive and the American Association for Cancer Research (AACR) partner to fund a two-year AACR-ALK Positive Lung Cancer Research Fellowship
ALK Positive Partners with AACR to Advance ALK-Positive Lung Cancer Research ALK Positive has partnered with the American Association for Cancer Research (AACR) to fund a two-year AACR–ALK Positive Lung Cancer Research Fellowship supporting early-career investigators in ALK-positive lung cancer research. The 2025 awardee, Alice Tzeng, MD, PhD of Dana-Farber Cancer Institute, is studying epigenetic…
-
ALK Positive Inc. Appoints Dr. Ken Culver as Executive Director & Medical Director to Lead Research and Patient Advocacy Initiatives
ALK Positive has appointed Dr. Ken Culver as Executive Director and Medical Director to guide the organization’s strategy and research investments. A physician-scientist with expertise in oncology and drug development, Dr. Culver has advanced patient-driven science and global collaborations since joining ALK Positive in 2022. His leadership marks an exciting new chapter in accelerating research…
-
Participate in Survey to Help our Medical Committee
The ALK Positive Inc. Medical Committee is seeking patient and caregiver input to enhance DDI Manager — an online resource that helps identify potential drug–drug interactions between cancer treatments and other medications. Your feedback can make a real difference in improving this tool for the entire ALK+ community. Participation takes just 10–15 minutes.
-
Takeda Oncology Co-Pay Assistance Progam
As of October 1, 2025, ALUNBRIG® (brigatinib) is now covered at Cigna Healthcare, giving most commercial patients faster access and lower out-of-pocket costs. With this update, about 99% of commercial lives are covered for ALUNBRIG. Learn more about co-pay assistance at takedaoncologycopay.com .
-
Managing Lorlatinib Together: What Patients and Experts Want You to Know
“Patients can—and should—have a voice in their care. This guide is about giving them the tools to do just that.” — Nancee Pronsati, ALK Positive Inc.
-
ALK Positive Announces Formation of Distinguished Scientific Advisory Board
ALK Positive, in collaboration with 23andMe Holding Co., a leading genetic health and biopharmaceutical company, and 20 lung cancer advocacy organizations, today announces a new study to help advance research in lung cancer. The focus of the Lung Cancer Genetics Study is to better understand the genetics of people with lung cancer in order to…
-
MEET YOUR STAFF: Introducing Sadia Yaakov, Medical Project Manager at ALK Positive, Inc
I was born and raised in Pennsylvania and had an interest in cancer research from the time that I was a child. I was exposed to Fox Chase Cancer Center very early on and knew from that moment that I wanted to do something to help in the fight against cancer. I attended University of…
-
Palliative Care for ALK-Positive Lung Cancer: Research Identifies a Vital Resource for Improving Quality of Life
For individuals diagnosed with ALK-positive lung cancer, the mention of palliative care can often lead to confusion or misunderstanding. Many wonder: Why is palliative care recommended? How does it fit into my treatment plan? Do I need it now, or is it something to consider later? Let’s look at the research and explore how palliative…
-
MEET YOUR STAFF: Introducing Katie Delaney, Philanthropy Operations Manager at ALK Positive, Inc.
With over a decade of entrepreneurship and management experience, I’ve learned one enduring truth: obstacles become opportunities when met with hard work and dedication. Believing that anything is possible with perseverance and self-belief, I’ve discovered that the greatest gift is empowering others to believe in themselves as well.
-
Break Through Cancer and ALK Positive, Inc. Team Up to Conquer ALK-Positive Lung Cancer with a $2 Million, Multi-year, Research Partnership
Break Through Cancer announces a new partnership with ALK Positive Inc. (ALK Positive), a foundation funded by patients with ALK-positive lung cancer and their families. ALK Positive and Break Through Cancer are joining forces to fund a new initiative in lung cancer research with the hope of creating durable responses and cures for patients with…